Matt Belvedere is a veteran journalist at the intersection of where live television news programs and the Internet meet—developing and managing an online and social media presence for CNBC's flagship morning show, "Squawk Box."
Following years of cable and major market live TV news production, Belvedere started in 2007 the award-winning video department at usnews.com, the website of U.S. News & World Report. He also managed online strategies there at a time when the magazine was transitioning to a digital first organization.
Belvedere was nominated for a local Emmy as the Producer of morning ratings leader "News4 Today" at WRC, the NBC-owned station in Washington, D.C.
Prior to WRC, he started his career in TV production at CNBC, where he returned in the fall of 2011 as a producer on "Street Signs," before joining the digital team.
—Follow Matt Belvedere on Twitter @Matt_Belvedere
U.S. stock futures were little changed on this final day of August. The Dow and S&P 500 were clinging to small monthly gains.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Apple will likely end up paying less than the eye-popping $14.5 billion the EU says is owed to Ireland in back taxes, an analyst says.
The EU this morning ordered the Irish government to claw back up to $14 billion plus interest in taxes from Apple. Ireland and Apple vowed to appeal.
This is how interest rates and the stock market can go both higher, says a top portfolio manager at ClearBridge.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
U.S. stock futures were drifting this morning, after the market closed lower last week, as U.S. central bankers suggested interest rates could be raised sooner than expected.
Federal Reserve Vice Chairman Stanley Fischer tells CNBC the decision on whether to hike interest rates should be looking forward not backward.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
Bill Ackman tells CNBC he was approached indirectly by Carl Icahn to purchase a stake in Herbalife — his longtime short target.